Healthcare / Medical Instruments & SuppliesTokyo
$2806.00
-44.00 (-1.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 27% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.1B · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$40.6B
P/E
13.6x
↓EV/EBITDA
3.1x
↓ROE
6.7%
↑Gross Margin
38.4%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
—
FCF margin
-1.3%
FCF / Net income
-0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.55B · net income $3.01B · FCF $-288.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.55B | $22.55B | $21.85B | $21.61B | $20.13B |
| Net Income | $3.01B | $3.01B | $3.07B | $2.86B | $2.99B |
| EBITDA | $6.36B | $6.36B | $6.33B | $5.62B | $5.75B |
| EPS | 204.55 | 204.55 | 187.95 | 170.67 | 178.14 |
| Gross Margin | 38.4% | 38.4% | 40.1% | 38.5% | 40.6% |
| Operating Margin | 19.9% | 19.9% | 21.4% | 19.1% | 22.0% |
| Net Margin | 13.4% | 13.4% | 14.0% | 13.3% | 14.9% |
| Balance Sheet | |||||
| Current Ratio | 6.25 | 6.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-288.1M | $-288.1M | $3.13B | $3.45B | $1.37B |
| Returns | |||||
| ROE | 6.7% | 6.7% | 7.0% | 6.1% | 6.5% |
| Valuation | |||||
| P/E | 13.60 | 13.60 | 15.64 | 14.24 | 13.17 |
| EV/EBITDA | 3.11 | 3.11 | 3.85 | 2.35 | 1.96 |
| P/B | 0.92 | 0.92 | 1.09 | 0.86 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | 3.2% | 3.2% | 1.1% | 7.3% | — |
| EPS Growth | 8.8% | 8.8% | 10.1% | -4.2% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.8%
EPS terminal req.
$248.99
Spread vs growth
2.1%
5Y implied EPS CAGR
8.1%
EPS terminal req.
$301.27
Spread vs growth
0.8%
10Y implied EPS CAGR
9.0%
EPS terminal req.
$485.20
Spread vs growth
-0.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.4%
Start / end P/E
13.5x → 13.7x
EPS bridge
187.95 → 204.55
Residual
+0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.